- Home
- OSTX vs TLSA Comparison
OSTX vs TLSA Comparison
Compare OSTX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- TLSA
- Stock Information
- Founded
- OSTX 2018
- TLSA 2013
- Country
- OSTX United States
- TLSA United Kingdom
- Employees
- OSTX N/A
- TLSA N/A
- Industry
- OSTX
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- TLSA Health Care
- Exchange
- OSTX NYSE
- TLSA Nasdaq
- Market Cap
- OSTX 86.5M
- TLSA 87.8M
- IPO Year
- OSTX 2024
- TLSA 2000
- Fundamental
- Price
- OSTX $2.25
- TLSA $0.89
- Analyst Decision
- OSTX Strong Buy
- TLSA
- Analyst Count
- OSTX 1
- TLSA 0
- Target Price
- OSTX $21.00
- TLSA N/A
- AVG Volume (30 Days)
- OSTX 19.7K
- TLSA 384.8K
- Earning Date
- OSTX 11-26-2024
- TLSA 12-27-2024
- Dividend Yield
- OSTX N/A
- TLSA N/A
- EPS Growth
- OSTX N/A
- TLSA N/A
- EPS
- OSTX N/A
- TLSA N/A
- Revenue
- OSTX N/A
- TLSA N/A
- Revenue This Year
- OSTX N/A
- TLSA N/A
- Revenue Next Year
- OSTX $9,900.00
- TLSA N/A
- P/E Ratio
- OSTX N/A
- TLSA N/A
- Revenue Growth
- OSTX N/A
- TLSA N/A
- 52 Week Low
- OSTX $2.10
- TLSA $0.41
- 52 Week High
- OSTX $4.90
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- TLSA 44.59
- Support Level
- OSTX N/A
- TLSA $0.87
- Resistance Level
- OSTX N/A
- TLSA $1.27
- Average True Range (ATR)
- OSTX 0.00
- TLSA 0.10
- MACD
- OSTX 0.00
- TLSA -0.01
- Stochastic Oscillator
- OSTX 0.00
- TLSA 5.13
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.